CYP has reported encouraging early safety and efficacy data in its Phase 1 trial of CYP-001 in GvHD. Shaw and Partners, forecasts, recommendation and 12 month TP ($1.20) remain unchanged. BUY.
Respected Wall Street analyst Dr Raghuram Selvaraju has published a research update on Cynata, reiterating the “buy” recommendation and price target of $1.50
Respected Wall Street analyst Dr Raghuram Selvaraju has published a research update on Cynata, reiterating the “buy” recommendation and price target of $1.50
Using our valuation model and taking into account the future revenues from its Cymerus™ platform, the company’s current total value should be AUD 150-175 million, or AUD 1.67-1.95 per share. This represents a substantial upside from the current share price
Respected Wall Street analyst Dr Raghuram Selvaraju has published new research on Cynata: “Raising price target—anticipating further milestones near-term. We believe that Cynata is entering a catalyst-rich period, with the possible option exercise near-term in its arrangement with Fujifilm...”